Charming Medical Ltd MCTA
Last close
—
Market cap
—
52-week range
— - —
No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.
Valuation FY2025 figures against the last close
P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS0.00
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $2.6M | $3.6M | $3.7M | — |
| Cost of revenue | $35.2K | $15.5K | $11.3K | — |
| Gross profit | $2.6M | $3.6M | $3.7M | — |
| Total operating expenses | $4.8M | $4.8M | $5.0M | — |
| Operating income | -$29.2K | $1.4M | $1.0M | — |
| Interest expense | $15.8K | $20.9K | $26.1K | — |
| Pre-tax income | $133.5K | $1.4M | $1.0M | — |
| Income tax | $156.1K | $236.1K | $181.8K | — |
| Net income | -$22.6K | $1.2M | $777.8K | — |
| EPS, basic | 0.00 | 0.08 | 0.05 | — |
| EPS, diluted | 0.00 | 0.08 | 0.05 | — |
| Shares, diluted (wtd. avg.) | 16.2M | 15.3M | 15.3M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash and equivalents | $4.7M | $816.8K | $2.1M | $1.9M |
| Receivables | $201.5K | $395.9K | — | — |
| Inventory | $25.6K | $26.8K | — | — |
| Total current assets | $8.2M | $3.4M | — | — |
| Property, plant and equipment | $606.9K | $500.1K | — | — |
| Total assets | $9.9M | $5.4M | — | — |
| Accounts payable | $415.3K | $246.5K | — | — |
| Short-term debt | $185.8K | $314.2K | — | — |
| Total current liabilities | $4.3M | $4.9M | — | — |
| Long-term debt | $185.8K | — | — | — |
| Total liabilities | $4.7M | $5.3M | — | — |
| Retained earnings | $96.8K | $119.4K | — | — |
| Total equity | $5.2M | $49.2K | -$1.1M | -$1.3M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Operating cash flow | -$1.2M | $425.9K | $295.4K | — |
| Depreciation and amortisation | $216.1K | $263.5K | $391.7K | — |
| Capital expenditure | $339.6K | $287.5K | $210.6K | — |
| Investing cash flow | -$179.0K | -$2.2M | -$210.6K | — |
| Financing cash flow | $5.3M | $521.3K | $100.1K | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-083325.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | — | $3.7M | $3.6M | $2.6M |
| Gross profit | — | $3.7M | $3.6M | $2.6M |
| Net income | — | $777.8K | $1.2M | -$22.6K |
Others in SIC 8090
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| DVA | DAVITA INC. | $11.74B | 18.7x | 6.5% |
| SHC | Sotera Health Co | $5.25B | 68.1x | 5.7% |
| PGNY | Progyny, Inc. | $2.16B | 43.3x | 10.4% |
| AGL | agilon health, inc. | $1.52B | — | -2.1% |
| VMD | VIEMED HEALTHCARE, INC. | $370.6M | 26.3x | 20.5% |
| CCEL | CRYO CELL INTERNATIONAL INC | $40.4M | — | -1.3% |
| BRTX | BioRestorative Therapies, Inc. | $40.3M | — | -10.3% |
| MGRX | MANGOCEUTICALS, INC. | $5.3M | — | -26.0% |